tbuckley/cabot-search huggingface dataset:
Erythema gyratum repens
Authors: R. Kurzrock
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Authors’ correction for Euro Surveill. 2020;25(23)
Journal: Eurosurveillance (2020)

© This work is licensed under a Creative Commons Attribution 4.0 International License. Closure This is a corrected article applying to the following content: Descriptive study of COVID-19 outbreak among passengers and crew on Diamond Princess cruise ship, Yokohama Port, Japan, 20 January to 9 February 2020
Pregnancy after embryo biopsy and coamplification of DNA from X and Y chromosomes
Authors: J. A. Grifo
Journal: JAMA (1992)

Reprint requests to Center for Reproductive Medicine and Infertility, Department of Obstetrics and Gynecology, Cornell University Medical College, 505 E 70th St, Room HT 300, New York, NY 10021 (Dr Grifo).
Errata
Journal: Environmental Health Perspectives (2013)

In "Materials and Methods" under "PP [protein phosphatase] activity after exposure to single MC congeners" (p.1371), some of the concentrations given for enzyme solution buffer and reaction buffer represent stock concentrations instead of final concentrations.The corrected text is as follows:Cells were exposed to varying concentrations of single MC congeners for 48 hr and solubilized in 50 μL enzyme solution buffer [52 mM Tris-HCl (pH 7.0), 0.1 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitol (DTT; in 0.01 M sodium acetate, pH 5.2), 2 mM manganese chloride (MnCl 2 )].Protein concentrations were determined using the method of Bradford (1976).Subsequently, 20 μL of each sample (containing 10 μg total protein) was transferred to a 96-well plate, and an equal volume of water was added.To determine PP activity, 200 μL freshly prepared and prewarmed (37°C) substrate solution containing reaction buffer [125 mM Tris-HCl (pH 8.1), 0.4 mM MnCl 2 , 52 mM magnesium chloride, 1 mg/mL bovine serum albumin (BSA)], 60 mM p-nitrophenyl phosphate (pNPP; Acros Organics, Morris Plains, NJ, USA), and 2 mM DTT were added and immediately measured at 405 nm (TECAN infinite M200; TECAN, Craislheim, Germany) to determine the 0-time value.These changes do not affect the results or conclusions of the paper.The authors regret the errors.
Hepatology Highlights
Authors: Kavitha M. Nair, Ravi S. Vora, Omar Y Mousa, Harmeet Malhi, Robert E. Schwartz, Joseph F. Pisa, Robert S. Brown, Hirsh D. Trivedi, Daryl T.Y. Lau, Nicole Shen, Akhil Shenoy, Jessica L. Maiers, Enis Kostallari, Petra Hirsova, Nicholas Russo, Tasha B. Kulai
Journal: Hepatology (2019)

Nair, Kavitha M.; Vora, Ravi S.; Mousa, Omar Y; Malhi, Harmeet; Schwartz, Robert E.; Pisa, Joseph F.; Brown, Robert S. Jr.; Trivedi, Hirsh D.; Lau, Daryl T.Y.; Shen, Nicole; Shenoy, Akhil; Maiers, Jessica L.; Kostallari, Enis; Hirsova, Petra; Russo, Nicholas; Kulai, Tasha B. Author Information
Vitamin A and the Susceptibility of Respiratory Tract Tissues to Carcinogenic Insult
Authors: P. Nettesheim, C. Snyder, J. C. S. Kim
Journal: Environmental Health Perspectives (1979)

The influence of vitamin A on the development of chemically induced lung carcinomas in rats was investigated. Rats were maintained on low, "normal" and excess levels of retinyl acetate (RA). Respiratory tract-squamous carcinomas were induced by intratracheal injections of 3-methylcholanthrene (3-MCA). The carcinogen doses used ranged from 1.25 to 10.0 mg of 3-MCA. Serial sacrifices conducted during the first 20 weeks following carcinogen exposure showed that metaplastic lung nodules, presumed to be precursors of later appearing carcinomas, occurred earlier and at higher incidence in rats maintained on low levels of RA than in rats maintained on moderate or high levels of RA. The development of invasive pulmonary carcinomas was enhanced at all four carcinogen doses in rats receiving low levels of RA as compared to rats receiving moderate or high levels of RA. No consistent difference in lung cancer incidence existed between the groups receiving normal and high levels of RA. The data clearly show an increased susceptibility of vitamin A-deficient rats to develop chemically induced lung cancers. Possible mechanisms underlying this effect are discussed.
Correlation between Cadmium-Induced Pulmonary Carcinogenicity, Metallothionein Expression, and Inflammatory Processes: A Species Comparison
Authors: G. Oberdorster, M. G. Cherian, R. B. Baggs
Journal: Environmental Health Perspectives (1994)

There is sufficient evidence for pulmonary carcinogenicity of inhaled Cd compounds in rats whereas no such evidence was found in mice and ham- sters; the evidence in humans has been termed limited, indicating significant species differences in pulmonary response to inhaled Cd.We hypothe- sized that expression of metallothionein (MT) protein in the lung after inhalation of Cd differs between species thereby providing different degrees of sequestration of Cd and protection from its effects.Rats and mice were exposed to 100 pg CdCI2 aerosols/mi3 for 4 weeks, and the presence of MT was determined in lung and free lung cell homogenates as well as by immunocytochemistry in lung sections up to 28 days postexposure.In addi- tion, pulmonary inflammatory, and cell proliferative responses were determined.Cd exposure significantly increased MT in homogenates of total lung in both species; however, no significant increase of MT in rat lung tissue after removal of free lung cells by lavage was found whereas MT was still significantly increased in lavaged mouse lung tissue throughout the postexposure time.In contrast, exposed rats showed significant increases in MT in the lavageable lung cells and mice did not.Histochemical analysis of lung sections revealed that mainly the epithelial cells of the bronchi, bronchioli, and alveoli of Cd-exposed mice expressed MT. Mice also exhibited a marked and sustained pulmonary inflammatory and cell proliferative response upon CdCI2 exposure which was not observed in rats.The retained Cd dose per gram lung was about 2-fold greater in mice, which is con- sistent with a greater deposition efficiency of inhaled Cd-aerosols in mice.The pulmonary Cd retention halftime was about twice as long in mice than in rats.The greater MT induction may offer an explanation for the resistance of mice toward the pulmonary carcinogenic effect of inhaled Cd despite a greater pulmonary inflammatory and cell proliferative effect and a greater retention halftime of lung Cd in this species.-
Autonomic neuropathy in advanced liver disease
Authors: F Trevisani, G Sica, M Bernardi
Journal: Hepatology (1996)

al. 1 on the poor prognostic meaning of the presence of auto-University of Bologna nomic neuropathy in patients awaiting liver transplantation Bologna, Italy (OLT).After two pioneering studies, 2,3 the authors again draw the attention of clinicians to the importance of the dys-
Compliance of the Lung During the First Week of Life
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
October 17, 2001
Journal: JAMA (2001)

Ian G. Stiell, MD, MSc, FRCPC; George A. Wells, PhD; Katherine L. Vandemheen, BScN; Catherine M. Clement, RN; Howard Lesiuk, MD; Valerie J. De Maio, MD, MSc; Andreas Laupacis, MD, MSc; Michael Schull, MD, MSc; R. Douglas McKnight, MD; Richard Verbeek, MD; Robert Brison, MD, MPH; Daniel Cass, MD; Jonathan Dreyer, MD; Mary A. Eisenhauer, MD; Gary H. Greenberg, MD; Iain MacPhail, MD, MHSc; Laurie Morrison, MD, MSc; Mark Reardon, MD; James Worthington, MBBS
Table of Contents
Authors: William Smoyer, Fredric Finkelstein, Mignon Mcculloch, Mary Carter, Ariane Brusselmans, John Feehally, Michael Rocco, Alfred Cheung, Madhav Menon, Michael Ross, Keizo Kanasaki, Hiroshi Nishi, Imari Mimura, Andrea Angioi, Fernando Fervenza, Sanjeev Sethi, Yuzhou Zhang, Richard Smith, David Murray, Jens Praet, Antonello Pani, An De Vriese, Tilman Drüeke, Ziad Massy, Akshaar Brahmbhatt, Andrea Remuzzi, Marco Franzoni, Sanjay Misra Open, Punithavathi Ranganathan, Rania Hamad, Riyaz Mohamed, Calpurnia Jayakumar, Thangaraju Muthusamy, Ganesan Ramesh, Jun Morinaga, Tsuyoshi Kadomatsu, Keishi Miyata, Motoyoshi Endo, Kazutoyo Terada, Zhe Tian, Taichi Sugizaki, Hiroki Tanigawa, Jiabin Zhao, Shunshun Zhu, Michio Sato, Kimi Araki, Ken-Ichi Iyama, Kengo Tomita, Masashi Mukoyama, Kimio Tomita, Kenichiro Kitamura, Yuichi Oike, Yang De Marinis, Mengyin Cai, Pradeep Bompada, David Atac, Olga Kotova, Martin Johansson, Eliana Garcia-Vaz, Maria Gomez, Markku Laakso, Leif Groop
Journal: Kidney International (2016)
E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
Authors: Howard S. Hochster, Paul J. Catalano, Edith P. Mitchell, Deirdre Jill Cohen, Peter J. O'Dwyer, Al Bowen Benson
Journal: Journal of Clinical Oncology (2014)

TPS3665 Background: Anti-angiogenic therapy for CRC has been accepted as standard therapy with approval of bevacizumab (bev) in both first-line and second-line settings. At the time this study was started, the benefit of continuing an anti-angiogenic in second line therapy was unproven. Ramucirumab (RAM, IMC 1121b) is a humanized antibody directed against the VEGF-R2 receptor, which may prove to have different activity compared to anti-VEGF antibody (bev). Additionally, while combining the anti-EGFR antibody, cetuximab (CMAB), with bev in first-line unselected patients was not effective, it is unknown whether the same may be true with RAM plus CMAB in a second-line setting for KRAS-selected patients. Methods: The study was designed as a randomized phase II trial with 147 patients assigned to IC = Irinotecan (I) 180 mg/m2 IV plus CMAB 500 mg/m2 IV q2w versus ICR = IC plus RAM 8 mg/kg IV q2w. Eligibility included prior treatment on one prior oxaliplatin and bev-containing regimen and progression within 42 days of last bev, PS 0-1, KRAS codon 12,13 wild-type and standard other chemo and bev criteria. Doses were modified for neutropenia, diarrhea, mucositis, rash and grade 3 other toxicities. The study was activated 10/8/10. After the first 35 patients were enrolled, accrual was held 6/24/12 for toxicity analysis per protocol. More grade 3 events of mucositis, diarrhea, neutropenia and perforation events (including peri-rectal abscesses) were seen in the ICR arm. The study has been modified to reflect the actual doses received, and will reopen with modified ICR (mICR) = I 150 mg/m2, CMAB 400 mg/m2 and RAM 6 mg/kg IV q2w. An additional 100 pts will be accrued to the revised study, giving 85% power to detect improved median PFS from 4.5 to 7.65 months. New eligibility criteria include any progression from 1st line chemo (on or off), normal albumin, no bowel perforation or obstruction in last 6 months. The revision was approved by CTEP in December 2013 and will re-open to accrual in March 2014, with SWOG participation. Clinical trial information: NCT01079780.
Passive smoking and heart disease. Mechanisms and risk
Authors: S. A. Glantz
Journal: JAMA (1995)

<h3>Objective.</h3> —Recent clinical, laboratory, and epidemiological evidence that passive smoking causes heart disease was reviewed, with particular emphasis on understanding the underlying physiological and biochemical mechanisms. <h3>Data Sources.</h3> —Publications in the peer-reviewed literature were located via MEDLINE, citation in other relevant articles, and appropriate reports by scientific agencies. Greatest emphasis was given to work published since 1990. <h3>Conclusions.</h3> —Passive smoking reduces the blood's ability to deliver oxygen to the heart and compromises the myocardium's ability to use oxygen to create adenosine triphosphate. These effects are manifest as reduced exercise capability in people breathing secondhand smoke. Secondhand smoke increases platelet activity, accelerates atherosclerotic lesions, and increases tissue damage following ischemia or myocardial infarction. The effects of secondhand tobacco smoke on the cardiovascular system are not caused by a single component of the smoke, but rather are caused by the effects of many elements, including carbon monoxide, nicotine, polycyclic aromatic hydrocarbons, and other, not fully specified elements in the smoke. Nonsmokers exposed to secondhand smoke in everyday life exhibit an increased risk of both fatal and nonfatal cardiac events. (<i>JAMA</i>. 1995;273:1047-1053)
Travellers' diarrhoea.
Authors: M J Farthing
Journal: Gut (1994)

Leading article -Tropical infection ofthe gastrointestinal tract and liver seres Travellers' diarrhoea This is thefirst ofa series ofleading articles concerning tropical infection ofthe gastrointestinal tract and liver.The editorial committee is most gratefulto Dr Gordon Cook, the series editor, and his contributors for their timely contributions to thejournal.
Oral Contraception and Increased Risk of Cerebral Ischemia or Thrombosis
Journal: New England Journal of Medicine (1973)

A case–control study was conducted to determine the relation between the use of oral contraceptives and the occurrence of stroke in young women. During a two-year period between 1969 and 1971, neurologists from 12 university hospitals identified various types of cerebrovascular disease in 598 nonpregnant women 15 to 44 years of age. Control subjects matched for age, sex and race were chosen from the discharge rosters of the same hospitals and from women residing in the same neighborhood as the patients with stroke. A detailed history of contraceptive practices was obtained by lay interviewers from approximately 70 per cent of patients and controls. The current use of oral contraceptives was considerably increased in women with thrombotic strokes as compared with their controls and somewhat increased in women with hemorrhagic strokes. The relative risk of cerebral ischemia or thrombosis was estimated to be about nine times greater for women who use oral contraceptives than for those who do not. (N Engl J Med 288:871–878, 1973)
POISONING BY WOOD ALCOHOL.CASES OF DEATH AND BLINDNESS FROM COLUMBIAN SPIRITS AND OTHER METHYLATED PREPARATIONS.
Authors: FRANK BULLER
Journal: JAMA (1904)

Cases27 and 28.— (From Dr. Frank A. Grawn, Munising, Mich.; Dr. T. W. Scholtes, Munising, Mich.) J. B., aged 37, nationality French, occupation woodsman, date of death, Nov. 14, 1898. L. B., aged 40, nationality French, occupation woodsman, date of death, Nov. 14, 1898. Symptoms, in both cases, great suffering from pain in abdomen, especially in region of stomach, vomiting, severe headache, total blindness and severe prostration. The postmortem findings consisted principally of a marked congestion of the gastric mucosa, also of liver, kidneys and vessels of brain. The conclusions arrived at were that while the local changes produced by this alcohol were quite prominent, death was undoubtedly due to the sys'emic effect of the poison. These two men who died from the poisoning were brothers. They came to Munising, went to a saloon and, as they stated, called for "good" alcohol. The saloonkeeper says he understood them to say "wood" alcohol.
Book Reviews
Authors: D. B. MCGUIRE
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Book Reviews Get access The Cancer Experience: Nursing Diagnosis and Management . Doris L. Carnevali , Ann C. Reiner . Philadelphia : J. B. Lippincott , 1990 , 496 pp.$27.50. DEBORAH B. MCGUIRE DEBORAH B. MCGUIRE The Johns Hopkins University School of Nursing and Nursing Department The Johns Hopkins Oncology Center600 N Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 2, 16 January 1991, Pages 134–135, https://doi.org/10.1093/jnci/83.2.134 Published: 16 January 1991
Hyperprolactinemia
Authors: Nicholas A. Tritos, Anne Klibanski
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The frail, the old, and diagnosis related groups
Authors: Milford Fulop
Journal: JAMA (1987)

<h3>To the Editor.—</h3> The present diagnosis related groups recognize the greater difficulty and cost of caring for elderly patients by providing higher reimbursement in some diagnostic categories for those over 70 years of age than for younger patients. That permits hospitals the option of either providing more nursing care (or other support) for patients over 70 years of age or else keeping them longer. However, that does not go far enough. Physicians who care for elderly patients know that they are often weaker, more fragile, and slower than younger people. Those difficulties are<i>far</i>greater in patients over 75 to 80 years of age. Just as it is more difficult to care for the average 70-year-old than the average 50-year-old who has the same illness, it is far more difficult and time-consuming to care for the average 80-year-old. Such patients are usually much more difficult and slower to return to
Publications du Progres Medical.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Addendum
Authors: Donald J. Ostrow, Montgomery D. Bissell
Journal: Hepatology (2008)

Paul Berk provides a vignette1 that further illustrates Rudi Schmid's intrinsic honesty and fairness, as highlighted in the obituary we published in the February issue of Hepatology.2 There is an amusing sequel to Paul's story. By the mid 1970s, Rudi had became so converted to Paul's concepts that he presented a six-compartment model of bilirubin kinetics3 at an international meeting. In his discussion of Rudi's paper, Paul brought down the house with his opening comment to Rudi, "You've come a long way baby!" Paul then deftly dissected the problems created with the accuracy of kinetic constants derived by modeling so many compartments. We also wish to add that John Vierling was inadvertently omitted from our list of Rudi's trainees who became president of the American Association for the Study of Liver Diseases, raising that total to nine.2
Lower Extremity Amputation Episodes Among Persons With Diabetes—New Mexico, 2000
Journal: JAMA (2003)

Lower extremity amputation (LEA) is one of the most disabling complications of diabetes. Lower extremity problems tend to recur among persons because of underlying complications, including the loss of "protective" sensation. To define the burden of LEA among persons with diabetes in New Mexico, the New Mexico Diabetes Prevention and Control Program (DPCP) analyzed data from the Hospital Inpatient Discharge Database (HIDD) and the Santa Fe Indian Hospital (SFIH) from 2000 by linking hospital discharges to persons to create "episodes" of LEA. This report summarizes the findings of that analysis, which indicated that the age-adjusted rate of LEA by episode was approximately 3.5 times higher for American Indians (AIs) (11.4 per 1,000 persons with diabetes) than for non-Hispanic whites (3.3). To address this disparity, DPCP is collaborating with the Indian Health Service (IHS) to determine the needs for foot-care resources and education in AI communities.